Zenotech Laboratories Ltd

Dematerialisation status

• Dematerialisation requests processed; securities listed on exchanges.
• Physical certificates for dematerialisation mutilated and cancelled; depository named as registered owner within 15 days.
• Certificate confirming above issued to depositories and stock exchanges.

Zenotech Laboratories Limited trading window closed from October 01, 2026 until 48 hours after the declaration of Unaudited Financial Results for the quarter and half year ending September 30, 2026

AGM details

• Date and time: September 25, 2026, 10:30 AM IST
• Mode: Video Conferencing/OAVM
• Record date for voting: September 18, 2026

Resolutions put to vote

• Ordinary: Adoption of audited standalone financial statements for FY2026
• Ordinary: Re-appointment of director Jignesh Anantray Goradia on rotation
• Ordinary: Approval for material related party transactions with Sun Pharmaceutical Industries Limited

Voting results

• Resolution 1 passed: 99.95% in favour, 0.05% against
• Resolution 2 passed: 99.85% in favour, 0.15% against
• Resolution 3 passed: 78.17% in favour, 21.83% against

Material related party transactions

• Counterparty: Sun Pharmaceutical Industries Limited
• Nature: approval for material related party transactions
• Value: not disclosed

Director changes

• Jignesh Anantray Goradia re-appointed on rotation

AGM Details

• AGM held Sep 25, 2026 from 10:30 to 11:30 IST via Video Conferencing.

Key Resolutions Passed

• Adoption of audited standalone financial statements for FY ended Mar 31, 2026.
• Re-appointment of director by rotation.
• Approval for material related party transaction with Sun Pharmaceutical Industries Limited.

Voting Results

• All resolutions approved by shareholders with requisite majority.
• No dissent details provided.

Related Party Transactions

• Approval granted for material RPT with Sun Pharmaceutical Industries Limited.

Financial highlights

• FY26 revenue from operations ₹3,956.20 lakh, up 1.5% YoY.
• Total revenue ₹4,592.26 lakh; net loss after tax ₹107.21 lakh.
• EPS (basic/diluted) ₹(0.18).
• Cash & equivalents ₹3,028.93 lakh; no debt (debt-free).
• Current ratio 3.40x; dividend declared: none.

Revenue model & customer

• All FY26 revenue from Sun Pharma group; 100% of revenue source.
• Contract manufacturing and biotech/asset leasing arrangements with Sun Pharma.
• Six material related party transactions with Sun Pharma totaling ₹200 crore for FY26.

Capital structure & liquidity

• Equity share capital standstill at ₹6,103.06 lakh (61,030,568 shares).
• No borrowings; balance sheet shows ₹0 debt outstanding.
• Year-end cash ₹3,028.93 lakh; current ratio 3.40x.

Related party transactions & governance

• Sun Pharma holds 68.84% of Zenotech; related party transactions reviewed by Audit Committee.
• RPTs approved omnibus by Audit Committee; Board recommended to members.
• Sun Pharma is holding/promoter; no KMP interest in the transactions.

Board, auditors & governance

• Board of 6 directors; 3 independent; one woman director.
• Nikkhil Kothhari appointed Independent Director 23 Jan 2026; regularized 11 Mar 2026.
• Chintan Shah retired as Independent Director on 26 Jan 2026.
• Statutory Auditor: M/s G S K A & Co; unmodified opinion.
• Secretarial Auditor: Mahadev Tirunagari; Emphasis on legacy record gaps for overseas subsidiaries.

CSR & ESG

• CSR spent ₹20.59 million; 2% of average net profit requirement ₹24.22 million.
• Shortfall ₹3.63 million; unspent CSR ₹32,694 for set-off.
• Solar power installed: 1 MW; CSR policy accessible on company website.

Risks, regulatory & disclosures

• Overseas subsidiaries’ missing records preclude consolidated statements; no Ind AS 110 consolidation.
• Contingent liabilities include tax and customs matters; ongoing litigations with legacy promoters noted.
• Green initiative: AGM notices and documents sent electronically; e-voting window 22–24 Sep 2026.

AGM Details

• Date and time: 25 September 2026 at 10:30 IST.
• Mode: Video Conferencing.
• Cut-off date for voting eligibility: 18 September 2026.

Financial results overview

• Revenue from operations: Rs 959.64 lakh; QoQ +8.2%; YoY +11.0%.
• Total income: Rs 1,104.79 lakh; QoQ +5.4%.
• Employee benefits: Rs 491.63 lakh; Depreciation: Rs 190.23 lakh.
• Other expenses: Rs 483.00 lakh; Total expenses: Rs 1,164.86 lakh.
• Loss after tax: Rs 45.55 lakh; basic/diluted EPS: Rs -0.07.
• Total comprehensive loss: Rs 44.38 lakh.
• Single reportable segment: Pharmaceuticals.
• Overseas subsidiaries defunct; no consolidated results.
• Auditor’s review: unaudited standalone; limited review with unmodified conclusion.
• Paid-up equity: Rs 6,103.06 lakh; Reserves: Rs 3,409.05 lakh.
• Other operating income: Rs 101.58 lakh; rentals to Sun Pharma for R&D.
• Year ended 31.03.2026: Total income Rs 4,592.26 lakh; EPS 0.16.
• Board approved the results; quarter ended June 30, 2026.